EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) have exhibited clinically significant therapeutic responses in non-small cell lung cancer (NSCLC) patients with tumors that harbor the most frequent EGFR driver mutations [1–3].